PFE Pfizer Inc
Q3 2025 10-Q
Pfizer Inc (PFE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Revenue $16.7B Q3 2025, down 6% YoY from $17.7B, driven by $1.3B operational decline mainly due to Paxlovid (-55%) and Comirnaty (-20%)
- • Income from continuing ops before tax $3.3B Q3 2025 vs $4.7B Q3 2024; operating margin approx. 19.8% Q3 2025 vs 26.5% Q3 2024 (revenue-based approximation)
Risk Factors
- • New product withdrawal risk: Voluntary withdrawal of Oxbryta in 2024 due to safety concerns, with EMA maintaining suspension and FDA review ongoing
- • Material regulatory update: IRA Medicare Part D Redesign in 2025 expected to reduce revenue by ~$1 billion, impacting pricing and manufacturer discounts
Quarterly Financial SummaryXBRL
Revenue
$16.7B
▼ -5.9% YoY▲ +13.7% QoQ
Net Income
$3.5B
▼ -20.7% YoY▲ +21.7% QoQ
Net Margin
21.3%
▼ -396bp YoY▲ +141bp QoQ
ROE
3.8%
Total Assets
$208.7B
EPS (Diluted)
$0.62
▼ -21.5% YoY▲ +21.6% QoQ
Operating Cash Flow
$4.6B
▼ -31.4% YoY▲ +890.9% QoQ
Source: XBRL data from Pfizer Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Pfizer Inc Quarterly Reports
Get deeper insights on Pfizer Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.